Symbols / BCRX
BCRX Chart
About
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. It also engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 1.89B |
| Enterprise Value | 2.07B | Income | -8.78M | Sales | 599.82M |
| Book/sh | -1.84 | Cash/sh | 1.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 580 | IPO | — |
| P/E | — | Forward P/E | 17.72 | PEG | — |
| P/S | 3.15 | P/B | -4.13 | P/C | — |
| EV/EBITDA | 25.77 | EV/Sales | 3.46 | Quick Ratio | 1.60 |
| Current Ratio | 1.87 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.05 | EPS next Y | 0.43 | EPS Growth | — |
| Revenue Growth | 36.10% | Earnings | 2026-02-26 | ROA | 10.31% |
| ROE | — | ROIC | — | Gross Margin | 68.43% |
| Oper. Margin | 18.57% | Profit Margin | -1.46% | Shs Outstand | 248.04M |
| Shs Float | 182.84M | Short Float | 15.96% | Short Ratio | 8.25 |
| Short Interest | — | 52W High | 11.31 | 52W Low | 6.00 |
| Beta | 0.79 | Avg Volume | 4.18M | Volume | 664.64K |
| Target Price | $21.20 | Recom | Strong_buy | Prev Close | $7.61 |
| Price | $7.62 | Change | 0.13% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.20
Mean price target
2. Current target
$7.62
Latest analyst target
3. DCF / Fair value
$4.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.62
Low
$13.00
High
$32.00
Mean
$21.20
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-30 | main | RBC Capital | Outperform → Outperform | $13 |
| 2025-12-15 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-11-05 | main | Citizens | Market Outperform → Market Outperform | $25 |
| 2025-11-04 | main | Barclays | Equal-Weight → Equal-Weight | $9 |
| 2025-11-04 | main | Needham | Buy → Buy | $18 |
| 2025-10-15 | main | Cantor Fitzgerald | Overweight → Overweight | $26 |
| 2025-10-15 | main | JMP Securities | Market Outperform → Market Outperform | $27 |
| 2025-10-15 | main | Needham | Buy → Buy | $20 |
| 2025-08-04 | main | Needham | Buy → Buy | $17 |
| 2025-07-01 | main | B of A Securities | Buy → Buy | $15 |
| 2025-06-30 | reit | RBC Capital | Outperform → Outperform | $13 |
| 2025-06-30 | main | Wedbush | Outperform → Outperform | $18 |
| 2025-06-27 | reit | Needham | Buy → Buy | $17 |
| 2025-06-25 | reit | Needham | Buy → Buy | $17 |
| 2025-05-07 | main | Barclays | Equal-Weight → Equal-Weight | $11 |
| 2025-05-06 | reit | RBC Capital | Outperform → Outperform | $13 |
| 2025-05-06 | main | JP Morgan | Overweight → Overweight | $13 |
| 2025-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-05-06 | main | Needham | Buy → Buy | $17 |
| 2025-04-29 | init | Cantor Fitzgerald | — → Overweight | $20 |
- Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Pressure And Rare Disease Pipeline Focus - Yahoo Finance Sat, 24 Jan 2026 08
- Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Rebound - simplywall.st Mon, 23 Feb 2026 14
- Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition - Bitget Mon, 23 Feb 2026 22
- BioCryst: A Changed And Interesting Thesis For 2026 (NASDAQ:BCRX) - Seeking Alpha ue, 20 Jan 2026 08
- BioCryst lines up March 3 slot at T.D. Cowen health care conference - Stock Titan ue, 17 Feb 2026 12
- Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth - Finviz Mon, 23 Feb 2026 16
- Insider Sale: Chief Legal Officer of $BCRX Sells 19,770 Shares - Quiver Quantitative Wed, 03 Dec 2025 08
- (BCRX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily Wed, 18 Feb 2026 05
- New HAE shot every 3–6 months? BioCryst’s $700M bet on Astria - Stock Titan Fri, 23 Jan 2026 08
- $BCRX stock is down 8% today. Here's what we see in our data. - Quiver Quantitative ue, 14 Oct 2025 07
- Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st hu, 06 Nov 2025 08
- BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance hu, 19 Feb 2026 15
- BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock? - Yahoo Finance hu, 16 Oct 2025 07
- Are Options Traders Betting on a Big Move in BCRX Stock? - Yahoo Finance ue, 12 Aug 2025 07
- Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX - Yahoo Finance Wed, 15 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 14854 | — | — | Stock Award(Grant) at price 0.00 per share. | MILNE JILL C. PH.D. | Director | — | 2026-01-23 00:00:00 | D |
| 1 | 21773 | 166563 | — | Sale at price 7.65 per share. | BARNES ALANE P | Officer | — | 2025-12-22 00:00:00 | D |
| 2 | 74233 | 371896 | — | Conversion of Exercise of derivative security at price 3.22 - 5.51 per share. | GAYER CHARLES K | President | — | 2025-12-22 00:00:00 | D |
| 3 | 20000 | — | — | Stock Gift at price 0.00 per share. | STONEHOUSE JON P | Chief Executive Officer | — | 2025-12-18 00:00:00 | D |
| 4 | 121700 | — | — | Stock Award(Grant) at price 0.00 per share. | BARNES ALANE P | Officer | — | 2025-12-17 00:00:00 | D |
| 5 | 471000 | — | — | Stock Award(Grant) at price 0.00 per share. | GAYER CHARLES K | President | — | 2025-12-17 00:00:00 | D |
| 6 | 121700 | — | — | Stock Award(Grant) at price 0.00 per share. | GHIAS BABAR | Chief Financial Officer | — | 2025-12-17 00:00:00 | D |
| 7 | 21210 | 162256 | — | Sale at price 7.65 per share. | BARNES ALANE P | Officer | — | 2025-12-15 00:00:00 | D |
| 8 | 161680 | 1164967 | — | Sale at price 7.10 - 7.65 per share. | BARNES ALANE P | Officer | — | 2025-12-03 00:00:00 | D |
| 9 | 91004 | 293033 | — | Conversion of Exercise of derivative security at price 3.22 per share. | BARNES ALANE P | Officer | — | 2025-12-01 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -134.61K | -6.31M | -416.43K | 14.89M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | 13.45M | -86.28M | -141.87M | -176.88M |
| TotalUnusualItems | -641.00K | -30.06M | -1.98M | 55.14M |
| TotalUnusualItemsExcludingGoodwill | -641.00K | -30.06M | -1.98M | 55.14M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -88.88M | -226.54M | -247.12M | -184.06M |
| ReconciledDepreciation | 1.25M | 1.66M | 1.44M | 777.00K |
| ReconciledCostOfRevenue | 12.48M | 4.66M | 6.59M | 7.26M |
| EBITDA | 12.81M | -116.33M | -143.85M | -121.74M |
| EBIT | 11.56M | -117.99M | -145.29M | -122.52M |
| NetInterestIncome | -83.77M | -92.46M | -93.97M | -59.23M |
| InterestExpense | 98.52M | 108.24M | 99.09M | 59.29M |
| InterestIncome | 14.75M | 15.78M | 5.13M | 62.00K |
| NormalizedIncome | -88.37M | -202.79M | -245.55M | -224.32M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -88.88M | -226.54M | -247.12M | -184.06M |
| TotalExpenses | 453.25M | 435.12M | 419.26M | 334.89M |
| TotalOperatingIncomeAsReported | -2.54M | -103.71M | -148.44M | -177.72M |
| DilutedAverageShares | 206.70M | 192.20M | 185.91M | 179.12M |
| BasicAverageShares | 206.70M | 192.20M | 185.91M | 179.12M |
| DilutedEPS | -0.43 | -1.18 | -1.33 | -1.03 |
| BasicEPS | -0.43 | -1.18 | -1.33 | -1.03 |
| DilutedNIAvailtoComStockholders | -88.88M | -226.54M | -247.12M | -184.06M |
| NetIncomeCommonStockholders | -88.88M | -226.54M | -247.12M | -184.06M |
| NetIncome | -88.88M | -226.54M | -247.12M | -184.06M |
| NetIncomeIncludingNoncontrollingInterests | -88.88M | -226.54M | -247.12M | -184.06M |
| NetIncomeContinuousOperations | -88.88M | -226.54M | -247.12M | -184.06M |
| TaxProvision | 1.93M | 310.00K | 2.73M | 2.25M |
| PretaxIncome | -86.95M | -226.23M | -244.38M | -181.81M |
| OtherIncomeExpense | -641.00K | -30.06M | -1.98M | 55.14M |
| SpecialIncomeCharges | 0.00 | -29.02M | 0.00 | 55.84M |
| OtherSpecialCharges | 29.02M | -55.84M | ||
| GainOnSaleOfSecurity | -641.00K | -1.04M | -1.98M | -695.00K |
| NetNonOperatingInterestIncomeExpense | -83.77M | -92.46M | -93.97M | -59.23M |
| InterestExpenseNonOperating | 98.52M | 108.24M | 99.09M | 59.29M |
| InterestIncomeNonOperating | 14.75M | 15.78M | 5.13M | 62.00K |
| OperatingIncome | -2.54M | -103.71M | -148.44M | -177.72M |
| OperatingExpense | 440.77M | 430.46M | 412.67M | 327.63M |
| ResearchAndDevelopment | 174.64M | 216.57M | 253.30M | 208.81M |
| SellingGeneralAndAdministration | 266.13M | 213.89M | 159.37M | 118.82M |
| GrossProfit | 438.23M | 326.75M | 264.23M | 149.91M |
| CostOfRevenue | 12.48M | 4.66M | 6.59M | 7.26M |
| TotalRevenue | 450.71M | 331.41M | 270.83M | 157.17M |
| OperatingRevenue | 450.71M | 331.41M | 270.83M | 157.17M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 208.54M | 205.77M | 187.91M | 184.35M |
| ShareIssued | 208.54M | 205.77M | 187.91M | 184.35M |
| NetDebt | 691.21M | 700.62M | 428.51M | 81.07M |
| TotalDebt | 808.74M | 825.15M | 741.45M | 593.24M |
| TangibleBookValue | -475.93M | -455.53M | -294.60M | -106.99M |
| InvestedCapital | 319.99M | 355.74M | 438.68M | 478.47M |
| WorkingCapital | 261.58M | 345.98M | 410.99M | 462.42M |
| NetTangibleAssets | -475.93M | -455.53M | -294.60M | -106.99M |
| CapitalLeaseObligations | 12.82M | 13.88M | 8.17M | 7.78M |
| CommonStockEquity | -475.93M | -455.53M | -294.60M | -106.99M |
| TotalCapitalization | 319.99M | 355.74M | 438.68M | 478.47M |
| TotalEquityGrossMinorityInterest | -475.93M | -455.53M | -294.60M | -106.99M |
| StockholdersEquity | -475.93M | -455.53M | -294.60M | -106.99M |
| GainsLossesNotAffectingRetainedEarnings | 921.00K | 1.34M | 26.00K | 177.00K |
| OtherEquityAdjustments | 921.00K | 1.34M | 26.00K | 177.00K |
| RetainedEarnings | -1.77B | -1.68B | -1.45B | -1.21B |
| AdditionalPaidInCapital | 1.29B | 1.22B | 1.16B | 1.10B |
| CapitalStock | 2.08M | 2.06M | 1.88M | 1.84M |
| CommonStock | 2.08M | 2.06M | 1.88M | 1.84M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 966.35M | 972.49M | 844.60M | 695.14M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 805.97M | 822.50M | 739.08M | 591.42M |
| LongTermDebtAndCapitalLeaseObligation | 805.97M | 822.50M | 739.08M | 591.42M |
| LongTermCapitalLeaseObligation | 10.05M | 11.23M | 5.80M | 5.96M |
| LongTermDebt | 795.92M | 811.26M | 733.28M | 585.46M |
| CurrentLiabilities | 160.38M | 149.99M | 105.51M | 103.72M |
| OtherCurrentLiabilities | 32.68M | 23.57M | ||
| CurrentDeferredLiabilities | 0.00 | 1.22M | 1.42M | |
| CurrentDeferredRevenue | 0.00 | 1.22M | 1.42M | |
| CurrentDebtAndCapitalLeaseObligation | 2.77M | 2.65M | 2.37M | 1.82M |
| CurrentCapitalLeaseObligation | 2.77M | 2.65M | 2.37M | 1.82M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 48.63M | 36.52M | 22.12M | 20.67M |
| CurrentProvisions | 32.12M | 26.51M | 14.33M | 5.96M |
| PayablesAndAccruedExpenses | 44.19M | 60.75M | 65.46M | 73.85M |
| CurrentAccruedExpenses | 17.95M | 21.33M | 43.41M | 38.99M |
| Payables | 26.23M | 39.42M | 22.06M | 34.86M |
| OtherPayable | 14.59M | 18.52M | 7.70M | 4.43M |
| TotalTaxPayable | 410.00K | 2.62M | ||
| AccountsPayable | 11.64M | 20.89M | 14.36M | 27.81M |
| TotalAssets | 490.42M | 516.96M | 550.00M | 588.15M |
| TotalNonCurrentAssets | 68.45M | 20.99M | 33.50M | 22.02M |
| OtherNonCurrentAssets | 28.34M | 80.00K | 6.81M | 6.47M |
| InvestmentsAndAdvances | 20.32M | 0.00 | 18.08M | 6.83M |
| InvestmentinFinancialAssets | 6.83M | |||
| AvailableForSaleSecurities | 6.83M | |||
| NetPPE | 19.79M | 20.91M | 8.62M | 15.19M |
| AccumulatedDepreciation | -12.35M | -11.21M | -9.55M | -8.11M |
| GrossPPE | 32.13M | 32.12M | 18.17M | 23.30M |
| Leases | 10.36M | 10.21M | 10.14M | 9.83M |
| ConstructionInProgress | 97.00K | 0.00 | ||
| OtherProperties | 18.23M | 18.56M | 4.59M | 10.72M |
| MachineryFurnitureEquipment | 3.44M | 3.35M | 3.44M | 2.75M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 421.97M | 495.97M | 516.50M | 566.14M |
| OtherCurrentAssets | 13.75M | 19.54M | 12.59M | 9.99M |
| RestrictedCash | 210.00K | 1.80M | 1.47M | 3.35M |
| PrepaidAssets | 9.99M | |||
| Inventory | 8.09M | 28.68M | 27.53M | 15.79M |
| InventoriesAdjustmentsAllowances | -2.65M | -1.60M | -1.18M | -245.00K |
| OtherInventories | -23.19M | |||
| FinishedGoods | 7.76M | 6.24M | 4.81M | 709.00K |
| WorkInProcess | 16.15M | 17.59M | 14.99M | 9.67M |
| RawMaterials | 10.01M | 6.45M | 8.91M | 5.66M |
| Receivables | 79.07M | 56.95M | 50.60M | 29.41M |
| AccountsReceivable | 79.07M | 56.95M | 50.60M | 29.41M |
| CashCashEquivalentsAndShortTermInvestments | 320.85M | 388.99M | 424.31M | 507.60M |
| OtherShortTermInvestments | 216.14M | 278.34M | 119.54M | 3.21M |
| CashAndCashEquivalents | 104.71M | 110.64M | 304.77M | 504.39M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -53.14M | -97.31M | -163.20M | -144.54M |
| RepaymentOfDebt | -1.70M | -241.62M | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 300.00M | 73.07M | 293.87M |
| IssuanceOfCapitalStock | 34.00K | 342.00K | 190.00K | 50.06M |
| CapitalExpenditure | -1.12M | -2.17M | -1.35M | -2.38M |
| InterestPaidSupplementalData | 30.38M | 22.14M | 0.00 | 900.00K |
| IncomeTaxPaidSupplementalData | 1.60M | 1.43M | 3.54M | 118.00K |
| EndCashPosition | 106.32M | 112.45M | 306.24M | 507.73M |
| BeginningCashPosition | 112.45M | 306.24M | 507.73M | 274.35M |
| EffectOfExchangeRateChanges | -936.00K | 362.00K | 566.00K | 71.00K |
| ChangesInCash | -5.19M | -194.15M | -202.06M | 233.31M |
| FinancingCashFlow | -5.76M | 32.48M | 88.03M | 359.67M |
| CashFlowFromContinuingFinancingActivities | -5.76M | 32.48M | 88.03M | 359.67M |
| NetOtherFinancingCharges | -7.54M | -34.58M | 293.87M | |
| ProceedsFromStockOptionExercised | 3.44M | 8.34M | 14.77M | 15.73M |
| NetCommonStockIssuance | 34.00K | 342.00K | 190.00K | 50.06M |
| CommonStockIssuance | 34.00K | 342.00K | 190.00K | 50.06M |
| NetIssuancePaymentsOfDebt | -1.70M | 58.38M | 73.07M | 293.87M |
| NetShortTermDebtIssuance | 73.07M | 0.00 | ||
| ShortTermDebtPayments | 0.00 | 0.00 | ||
| ShortTermDebtIssuance | 73.07M | 0.00 | ||
| NetLongTermDebtIssuance | -1.70M | 58.38M | 73.07M | 293.87M |
| LongTermDebtPayments | -1.70M | -241.62M | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 300.00M | 73.07M | 293.87M |
| InvestingCashFlow | 52.59M | -131.50M | -128.24M | 15.80M |
| CashFlowFromContinuingInvestingActivities | 52.59M | -131.50M | -128.24M | 15.80M |
| NetInvestmentPurchaseAndSale | 53.72M | -129.33M | -126.89M | 18.19M |
| SaleOfInvestment | 320.48M | 385.08M | 117.40M | 28.20M |
| PurchaseOfInvestment | -266.76M | -514.41M | -244.28M | -10.01M |
| NetPPEPurchaseAndSale | -1.12M | -2.17M | -1.35M | -2.38M |
| PurchaseOfPPE | -1.12M | -2.17M | -1.35M | -2.38M |
| OperatingCashFlow | -52.02M | -95.14M | -161.85M | -142.16M |
| CashFlowFromContinuingOperatingActivities | -52.02M | -95.14M | -161.85M | -142.16M |
| ChangeInWorkingCapital | -87.28M | -32.40M | -58.95M | 8.12M |
| ChangeInOtherWorkingCapital | -1.23M | -109.00K | 1.28M | |
| ChangeInPayablesAndAccruedExpense | -62.38M | -16.81M | -22.36M | 43.58M |
| ChangeInAccruedExpense | 0.00 | 0.00 | 4.17M | |
| ChangeInInterestPayable | 0.00 | 0.00 | 4.17M | |
| ChangeInPayable | -62.38M | -16.81M | -22.36M | 39.41M |
| ChangeInAccountPayable | -62.38M | -16.81M | -22.36M | 39.41M |
| ChangeInPrepaidAssets | 1.96M | -6.82M | -2.58M | -7.16M |
| ChangeInInventory | -4.16M | -1.45M | -12.42M | -8.77M |
| ChangeInReceivables | -22.70M | -6.09M | -21.47M | -20.82M |
| OtherNonCashItems | 67.61M | 85.80M | 98.92M | 54.20M |
| StockBasedCompensation | 65.41M | 55.62M | 44.70M | 34.64M |
| AssetImpairmentCharge | 1.35M | 1.97M | 932.00K | 0.00 |
| AmortizationOfSecurities | -11.47M | -10.26M | -1.78M | -2.00K |
| DepreciationAmortizationDepletion | 1.25M | 1.66M | 1.44M | 777.00K |
| DepreciationAndAmortization | 1.25M | 1.66M | 1.44M | 777.00K |
| Depreciation | 1.25M | 1.66M | 1.44M | 777.00K |
| OperatingGainsLosses | 29.02M | -55.84M | ||
| NetIncomeFromContinuingOperations | -88.88M | -226.54M | -247.12M | -184.06M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BCRX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|